A share price of Pliant Therapeutics Inc [PLRX] is currently trading at $12.55, up 10.38%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PLRX shares have gain 16.85% over the last week, with a monthly amount drifted -7.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on December 08, 2023, and set its price target to $41. On May 18, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $48 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $44 on April 13, 2023. Stifel initiated its recommendation with a Buy and recommended $33 as its price target on December 14, 2022. JP Morgan started tracking with a Overweight rating for this stock on December 07, 2022, and assigned it a price target of $42. In a note dated September 01, 2022, Citigroup initiated an Buy rating and provided a target price of $36 on this stock.
Pliant Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $10.22 and $18.00. Currently, Wall Street analysts expect the stock to reach $35.5 within the next 12 months. Pliant Therapeutics Inc [NASDAQ: PLRX] shares were valued at $12.55 at the most recent close of the market. An investor can expect a potential return of 182.87% based on the average PLRX price forecast.
Analyzing the PLRX fundamentals
Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at -45.88%, Pretax Profit Margin comes in at -41.67%, and Net Profit Margin reading is -41.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.49 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.65 points at the first support level, and at 10.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.16, and for the 2nd resistance point, it is at 13.78.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pliant Therapeutics Inc [NASDAQ:PLRX] is 10.26. In addition, the Quick Ratio stands at 10.26 and the Cash Ratio stands at 1.99.
Transactions by insiders
Recent insider trading involved Coulie Bernard, President and CEO, that happened on Jan 17 ’25 when 52419.0 shares were sold. Chief Financial Officer, Cummings Keith Lamont completed a deal on Jan 17 ’25 to sell 20148.0 shares. Meanwhile, Chief Business Officer Hull Hans sold 15936.0 shares on Jan 17 ’25.
